Aripiprazole: Just another neuroleptic

Prescrire International

Volumn 14, Issue 79, 2005, Pages 163-167

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; FLUOXETINE; HALOPERIDOL DECANOATE; KETOCONAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PROTEINASE INHIBITOR; QUINIDINE; RISPERIDONE; HALOPERIDOL; NEW DRUG; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

AGRANULOCYTOSIS; AKATHISIA; ARTICLE; BIRTH DEFECT; BODY WEIGHT DISORDER; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; ECTOPIC PREGNANCY; EXTRAPYRAMIDAL SYNDROME; FETUS MORTALITY; GALLBLADDER DISEASE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LOW BIRTH WEIGHT; MORTALITY; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; QT PROLONGATION; RATING SCALE; RELAPSE; RETINA DEGENERATION; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA; TERATOGENICITY; TORSADE DES POINTES; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HALOPERIDOL; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 27144469609     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Schorderet M and Calenca A "Neuroleptiques (antipsychotiques)". In: Schorderet M et al. "Pharmacologie" Frison-Roche, Paris 1998: 397-413.
2. "Schizophrenia". In: Martindale The complete drug reference" 34th ed, The Pharmaceutical Press, London 2005: 665-666.
3. The National Institute for Clinical Excellence "A rapid and systematic review of atypical antipsychotics in schizophrenia" 21 September 2001: 15 pages.
4. Prescrire Editorial Staff "Psychiatric use of neuroleptics" Prescrire Int 1997; 6 (30): 119-122.
5. Prescrire Editorial Staff "Clozapine" Prescrire Int 1992; 1 (3): 99-101.
6. Prescrire Editorial Staff "Clozapine" Prescrire Int 2002; 11 (57): 3-6.
7. Prescrire Editorial Staff "Risperidone" Prescrire Int 1997: 6 (27): 2-4.
8. Prescrire Editorial Staff "Olanzapine" Prescrire Int 1999; 8 (43): 135-138.
9. Freedman R "Schizophrenia" N Engl J Med 2003; 349 (18): 1738-1749.
10. Bridler R and Umbricht D "Atypical antipsychotics in the treatment of schizophrenia" Swiss Med Wkly 2003; 133: 63-76.
11. Halliday J et al. "Nithsdale Schizophrenia surveys 23: movement disorders" Br J Psychiatry 2002; 181: 422-427.
12. Prescrire Editorial Staff "Risperidone: stroke" Prescrire Int 2003; 12 (64): 63.
13. Prescrire Editorial Staff "Olanzapine: stroke and death" Prescrire Int 2004, 13 (74): 226.
14. The European Medicines Agency - Committee for Proprietary Medicinal Products "European Public Assessment Report - Abilify - Scientific discussion" 4 June 2004: 29 pages.
15. Stahl SM "Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics" J Clin Psychiatry 2001; 62: 841-842 + 923-924.
16. US Food and Drug Administration "Abilifyo Summary of Product Characteristics" October 2004: 39 pages.
17. Prescrire Rédaction "Évaluation des symptômes psychotiques déficitaires et productifs" Rev Prescrire 1996; 16 (168): 824.
18. US Food and Drug Administration - Center for Drug Evaluation and Research "Application number 21-436. Statistical review" 13 August 2002: 21 pages.
19. US Food and Drug Administration - Center for Drug Evaluation and Research "Application number 21-436. Medical review" 12 June 2002: 232 pages.
20. Marder SR et al. "Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials" Schizophrenia Res 2003; 61: 123-136.
21. Kane JM et al. "Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder" J Clin Psychiatry 2002; 63 (9): 763-771.
22. Bowles TM and Levin GM "Aripiprazole: a new atypical antipsychotic drug" Ann Pharmacother 2003; 7: 687-694.
23. Potkin SG et al. "Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone versus placebo in patients with schizophrenia and schizoaffective disorder" Arch Gen Psychiatry 2003; 60: 681-690.
24. Pigott TA et al. "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study" J Clin Psychiatry 2003; 64: 1048-1056.
25. Kasper S et al. "Efficacy and safety of aripiprazole versus haloperidol for long-term maintenance treatment following acute relapse of schizophrenia" Int J Neuropsychopharmacol 2003; 6: 325-337.
26. Schönfelt-Lecuona C and Connemann BJ "Aripiprazole and Parkinson's disease psychosis" Am J Psychiatry 2004, 161 (2): 373-374.
27. "Haldolo:. In French datasheet compendium "Dictionnaire Vidal" Vidal, Issy-les-Moulineaux, 2005: 905-912.
28. "Haldol decanoateo:. In: "Physicians' Desk Reference" Thomson-PDR, Montvale 2004: 2443-2445.
29. Colonna L et al. "Dictionnaire des neuroleptiques" Baillière, Paris 1989: 21 + 153-155.
30. Prescrire Rédaction "Le segment-clé du mois: - prazole" Rev Prescrire 2002; 22 (227): 267.